Follicum pauses recruitment of patients in Phase II clinical trial of FOL-005 as a result of the ongoing COVID-19 pandemic
Follicum AB ("Follicum" or "the company") today announces that the company has decided to temporarily suspend the phase II study of the drug candidate FOL-005 recently initiated in Germany. This is due to government recommendations in Germany in light of the ongoing outbreak of COVID-19. The company intends to resume the recruitment of patients for the study as soon as the situation in Germany improves.Follicum's Phase II study of FOL-005 was initiated on March 9, 2020 and the recruitment of patients has so far progressed well. The study is being conducted at the Clinical Research Center